ProKidney Corp. (NASDAQ:PROK) Insider Purchases $75,000.00 in Stock

ProKidney Corp. (NASDAQ:PROK) insider Control Empresarial De Capital purchased 100,000 shares of the business’s stock in a transaction on Wednesday, April 16th. The shares were acquired at an average price of $0.75 per share, for a total transaction of $75,000.00. Following the completion of the acquisition, the insider now directly owns 73,430,330 shares in the company, valued at approximately $55,072,747.50. This represents a 0.14 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Control Empresarial De Capital also recently made the following trade(s):

• On Monday, April 14th, Control Empresarial De Capital bought 268,105 shares of ProKidney stock. The shares were bought at an average cost of $0.73 per share, for a total transaction of $195,716.65.
• On Thursday, April 10th, Control Empresarial De Capital acquired 1,032,218 shares of ProKidney stock. The shares were bought at an average cost of $0.61 per share, for a total transaction of $629,652.98.

ProKidney Trading Down 0.6 %

PROK stock traded down $0.01 during trading on Friday, reaching $0.79. 1,018,709 shares of the stock were exchanged, compared to its average volume of 687,286. ProKidney Corp. has a twelve month low of $0.46 and a twelve month high of $4.44. The firm’s 50 day moving average is $1.03 and its 200 day moving average is $1.51. The firm has a market cap of $231.49 million, a P/E ratio of -1.44 and a beta of 1.52.

ProKidney (NASDAQ:PROK) last posted its earnings results on Monday, March 17th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). The company had revenue of $0.08 million for the quarter. As a group, analysts predict that ProKidney Corp. will post -0.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ProKidney

Several institutional investors have recently bought and sold shares of PROK. XTX Topco Ltd bought a new position in shares of ProKidney during the third quarter valued at about $41,000. ProShare Advisors LLC lifted its position in shares of ProKidney by 57.3% during the 4th quarter. ProShare Advisors LLC now owns 30,879 shares of the company’s stock worth $52,000 after buying an additional 11,250 shares in the last quarter. Sei Investments Co. purchased a new position in shares of ProKidney in the 4th quarter worth approximately $69,000. Susquehanna Fundamental Investments LLC bought a new position in shares of ProKidney in the fourth quarter valued at approximately $88,000. Finally, JPMorgan Chase & Co. lifted its holdings in ProKidney by 65.1% during the third quarter. JPMorgan Chase & Co. now owns 46,830 shares of the company’s stock worth $90,000 after acquiring an additional 18,472 shares during the period. Institutional investors own 51.59% of the company’s stock.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.